Yuto Honda

Dr. Yuto Honda

Tokyo Institute of Technology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NFNatsumi Fukuhara
Natsumi Fukuhara
YHYuto Honda
Yuto Honda
NUNao Ukita
Nao Ukita
MMMakoto Matsui
Makoto Matsui
YMYutaka Miura
Yutaka Miura
Katsuyuki HoshinaKatsuyuki Hoshina
Katsuyuki Hoshina
Abdominal aortic aneurysm (AAA) is a life-threatening disease. However, no systemically injectable drug has been approved for AAA treatment due to low bioavailability. Polymeric micelles are nanomedicines that have the potential to improve therapeutic efficacy by selectively delivering drugs into disease sites, and research has mainly focused on cancer treatments. Here, we developed a statin-loaded polymeric micelle to treat AAAs in rat models. The micelle showed medicinal efficacy by preventing aortic aneurysm expansion in a dose-dependent manner. Furthermore, the micelle-injected group showed decreased macrophage infiltration and decreased matrix metalloproteinase-9 activity in cases of AAA.

28 November 2025 in Journal of Controlled Release
Verified
Journal Article
Open access
NMNozomi Matsudaira
Nozomi Matsudaira
YHYuto Honda
Yuto Honda
HKHiroaki Kinoh
Hiroaki Kinoh
XLXueying Liu
Xueying Liu
SNShuhei Nagao
Shuhei Nagao
NNNobuhiro Nishiyama
Nobuhiro Nishiyama
Adeno-associated virus (AAV) vectors have emerged as one of the most promising viral vectors for gene therapy due to their capacity for long-term transgene expression, strong safety profile and low pathogenicity, and have been applied to the treatment of refractory cancer such as glioblastoma (GBM). However, AAV-mediated cancer gene therapy faces significant obstacles, including poor tumor targeting and neutralization by pre-existing antibodies (Abs). In this study, we developed a novel GBM-targeted AAV delivery platform, the cyclic RGD-functionalized ternary complex (cRGD-ternary complex). This complex is constructed through the self-assembly of AAV, tannic acid, and cRGD-conjugated phenylboronic acid polymers. cRGD serves as a ligand targeting αvβ3/αvβ5 integrins, which are highly expressed on GBM cells. In vitro, the cRGD-ternary complex effectively evaded neutralizing Abs due to its polymer shell and maintained high gene transduction efficiency. In an orthotopic GBM mouse model, systemic administration of cRGD-ternary complex significantly enhanced gene transduction in tumors and achieved substantial tumor suppression over 24 days. Furthermore, the cRGD-ternary complex showed therapeutic efficacy comparable to AAV alone at three-fold higher dose, with negligible hepatotoxicity. This platform successfully integrates active tumor targeting, immune evasion, and efficient gene transduction, overcoming critical limitations of AAV and showing significant potential for GBM gene therapy.

19 March 2026 in Journal of Controlled Release
Verified
Journal Article
Open access
YXYao Xiao
Yao Xiao
YHYuto Honda
Yuto Honda
NMNozomi Matsudaira
Nozomi Matsudaira
HKHiroaki Kinoh
Hiroaki Kinoh
XSXin Shen
Xin Shen
NNNobuhiro Nishiyama
Nobuhiro Nishiyama
Adeno-associated virus (AAV) has emerged as a promising vector for gene therapy; however, its therapeutic efficacy is often limited by pre-existing and treatment-induced neutralizing antibodies (NAbs). To address this challenge, we developed an AAV-loaded ternary complex through the sequential assembly of AAV, tannic acid (TA), and phenylboronic acid (PBA)-modified block copolymers, protecting AAV from NAbs by polymer shielding. In this study, we systematically investigated the structural parameters of PBA-modified block copolymers and their impact on NAb evasion and immune responses. We found that the optimized polymer chain lengths of each segment enhanced NAb evasion efficacy in vitro and in vivo by increasing steric hindrance and complex stability while preserving AAV transduction efficiency through intracellular pH-responsive release. Furthermore, the optimized AAV ternary complexes achieved suppression of de novo NAb production by more than 50% compared with AAV alone following administration. These findings highlight the importance of polymer structure in balancing immune evasion and transduction and demonstrate that the structurally tuned AAV9 ternary complexes represent a promising strategy to broaden the clinical applicability of AAV-based gene therapy to seropositive patients.

3 July 2026 in Research Square
Verified
Preprint
Open access
PDF file
TMTakumi Matsuo
Takumi Matsuo
YHYuto Honda
Yuto Honda
TCToshizumi Chino
Toshizumi Chino
TNTakahiro Nomoto
Takahiro Nomoto
YOYuriko Osakabe
Yuriko Osakabe
NNNobuhiro Nishiyama
Nobuhiro Nishiyama
In vivo genome editing with CRISPR–Cas9 ribonucleoproteins (RNPs) holds substantial therapeutic promise, yet rapid bloodstream clearance and the absence of delivery systems capable of systemic tumor targeting have hindered its clinical translation. Herein, a supramolecular ternary complex platform is reported in which Cas9/sgRNA RNPs are co-assembled with tannic acid (TA) and phenylboronic acid (PBA)-conjugated polymers through sequential self-assembly, producing ~ 30 nm core–shell ternary complexes that protect RNPs from enzymatic degradation and dissociate selectively at endosomal pH. Upon intravenous administration in subcutaneous tumor-bearing mice, these ternary complexes exhibit prolonged blood circulation and preferential tumor accumulation, achieving 37.2% gene editing at tumor sites compared with only 1.5% for free RNPs. The platform successfully knocks out previously undruggable oncogenes including mutant KRAS and polo-like kinase 1 (PLK1), markedly suppressing tumor growth in vivo . By integrating sequential supramolecular self-assembly with stimuli-responsive cargo release, this strategy establishes a generalizable framework for systemically administered in vivo CRISPR therapeutics.